Redmile Group LLC acquired a new stake in shares of Humana Inc (NYSE:HUM) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,000 shares of the insurance provider’s stock, valued at approximately $248,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Fieldpoint Private Securities LLC bought a new position in shares of Humana in the 3rd quarter worth about $115,000. American Beacon Advisors Inc. bought a new position in shares of Humana in the 4th quarter worth about $122,000. ClariVest Asset Management LLC bought a new position in shares of Humana in the 3rd quarter worth about $144,000. YorkBridge Wealth Partners LLC lifted its position in shares of Humana by 99.0% in the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after buying an additional 297 shares during the last quarter. Finally, Daiwa SB Investments Ltd. lifted its position in shares of Humana by 44.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after buying an additional 220 shares during the last quarter. Hedge funds and other institutional investors own 96.36% of the company’s stock.
HUM has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 19th. Cowen restated a “buy” rating and issued a $285.00 price target on shares of Humana in a research report on Wednesday, December 13th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $230.00 price objective on shares of Humana in a report on Tuesday, December 5th. Jefferies Group raised shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 price objective on the stock in a report on Friday, January 12th. Finally, Oppenheimer increased their price objective on shares of Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Eight equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Humana presently has an average rating of “Buy” and an average target price of $270.47.
Humana stock opened at $272.73 on Monday. The company has a market cap of $37,550.64, a PE ratio of 23.33, a price-to-earnings-growth ratio of 1.48 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.85 and a current ratio of 1.85. Humana Inc has a 52 week low of $203.48 and a 52 week high of $293.35.
Humana (NYSE:HUM) last released its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The firm had revenue of $13.19 billion for the quarter, compared to analysts’ expectations of $13.14 billion. Humana had a net margin of 4.55% and a return on equity of 16.13%. Humana’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the company earned $2.34 EPS. equities research analysts forecast that Humana Inc will post 13.81 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be paid a dividend of $0.50 per share. This is a boost from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.73%. Humana’s dividend payout ratio (DPR) is presently 9.59%.
Humana declared that its board has approved a stock buyback plan on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.
In other Humana news, CEO Bruce D. Broussard sold 14,075 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $274.32, for a total transaction of $3,861,054.00. Following the transaction, the chief executive officer now owns 113,896 shares of the company’s stock, valued at approximately $31,243,950.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the transaction, the senior vice president now directly owns 9,888 shares in the company, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,721 shares of company stock worth $9,421,229. 0.60% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Redmile Group LLC Acquires New Position in Humana Inc (HUM)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/03/19/redmile-group-llc-acquires-new-position-in-humana-inc-hum.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.